Journal
SCIENCE ADVANCES
Volume 6, Issue 25, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/sciadv.aba5136
Keywords
-
Categories
Funding
- Singapore Ministry of Education [MOE2018-T2-1-005, MOE2019-T2-2-008, MOE2014-T3-1-006]
- NMRC Clinician Scientist-Individual Research Grant (CS-IRG) [MOHCIRG18nov-0007]
- National Research Foundation Singapore
- Singapore Ministry of Education under its Research Centres of Excellence initiative
Ask authors/readers for more resources
RNA editing introduces nucleotide changes in RNA sequences. Recent studies have reported that aberrant A-to-I RNA editing profiles are implicated in cancers. Albeit changes in expression and activity of ADAR genes are thought to have been responsible for the dysregulated RNA editome in diseases, they are not always correlated, indicating the involvement of secondary regulators. Here, we uncover DAP3 as a potent repressor of editing and a strong oncogene in cancer. DAP3 mainly interacts with the deaminase domain of ADAR2 and represses editing via disrupting association of ADAR2 with its target transcripts. PDZD7, an exemplary DAP3-repressed editing target, undergoes a protein recoding editing at stop codon [Stop -> Trp (W)]. Because of editing suppression by DAP3, the unedited PDZD7(WT), which is more tumorigenic than edited PDZD7(Stop518W), is accumulated in tumors. In sum, cancer cells may acquire malignant properties for their survival advantage through suppressing RNA editome by DAP3.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available